{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T20:21:06.029303+00:00","company":{"ticker":"ONCO","cik":1782107,"company_name":"Onconetix, Inc."},"pagination":{"limit":100,"returned":83,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Veru Inc.","detail":"asset_purchase","count":3,"first_seen":"2023-04-20T23:59:59+00:00","last_seen":"2024-04-26T23:59:59+00:00","evidence_fact_ids":[58397,109183,164794]},{"display_name":"Altos Ventures","detail":"equity_purchase","count":1,"first_seen":"2024-04-26T23:59:59+00:00","last_seen":"2024-04-26T23:59:59+00:00","evidence_fact_ids":[58398]},{"display_name":"Cardinal Health 105, LLC","detail":"supply","count":1,"first_seen":"2023-10-03T23:59:59+00:00","last_seen":"2023-10-03T23:59:59+00:00","evidence_fact_ids":[109182]},{"display_name":"H.C. Wainwright & Co., LLC","detail":"atm_program","count":1,"first_seen":"2023-03-29T23:59:59+00:00","last_seen":"2023-03-29T23:59:59+00:00","evidence_fact_ids":[168612]},{"display_name":"Laboratory Corporation of America Holdings","detail":"license","count":1,"first_seen":"2025-12-10T23:59:59+00:00","last_seen":"2025-12-10T23:59:59+00:00","evidence_fact_ids":[129527]},{"display_name":"Proteomedix AG","detail":"merger","count":1,"first_seen":"2023-12-27T23:59:59+00:00","last_seen":"2023-12-27T23:59:59+00:00","evidence_fact_ids":[85512]},{"display_name":"Proteomedix AG, the Sellers, and the Sellers’ Representative","detail":"merger","count":1,"first_seen":"2023-12-21T23:59:59+00:00","last_seen":"2023-12-21T23:59:59+00:00","evidence_fact_ids":[86626]},{"display_name":"Realbotix Corp., Simulacra Corporation, and Realbotix, LLC","detail":"merger","count":1,"first_seen":"2026-02-12T23:59:59+00:00","last_seen":"2026-02-12T23:59:59+00:00","evidence_fact_ids":[32587]},{"display_name":"WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC","detail":"asset_purchase","count":1,"first_seen":"2023-06-14T23:59:59+00:00","last_seen":"2023-06-14T23:59:59+00:00","evidence_fact_ids":[139165]},{"display_name":"a certain holder of existing preferred investment options","detail":"equity_purchase","count":1,"first_seen":"2023-08-01T23:59:59+00:00","last_seen":"2023-08-01T23:59:59+00:00","evidence_fact_ids":[125811]}],"lender":[{"display_name":"Keystone Capital Partners, LLC","detail":"loan","count":3,"first_seen":"2025-06-11T23:59:59+00:00","last_seen":"2025-09-04T23:59:59+00:00","evidence_fact_ids":[41909,42961,45569]},{"display_name":"Veru Inc.","detail":"loan","count":2,"first_seen":"2025-08-12T23:59:59+00:00","last_seen":"2025-09-04T23:59:59+00:00","evidence_fact_ids":[41911,42962]},{"display_name":"KCP Fund I, LLC","detail":"loan","count":1,"first_seen":"2025-09-04T23:59:59+00:00","last_seen":"2025-09-04T23:59:59+00:00","evidence_fact_ids":[41910]}],"ma_counterparty":[{"display_name":"Proteomedix AG","detail":"acquisition","count":1,"first_seen":"2024-02-27T23:59:59+00:00","last_seen":"2024-02-27T23:59:59+00:00","evidence_fact_ids":[71691]},{"display_name":"Veru Inc.","detail":"acquisition","count":1,"first_seen":"2023-04-20T23:59:59+00:00","last_seen":"2023-04-20T23:59:59+00:00","evidence_fact_ids":[164796]}]},"facts":[{"fact_type":"governance_change","fact_key":"eac92f135eb0603e05a1fff2a3f784adef65beea","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2026-05-19T20:05:26+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-05-21","item_codes_triggered":["5.03"],"summary_text":"Amended charter to effect a 1-for-10 reverse stock split of common stock, effective May 21, 2026"},"claim":"Onconetix, Inc.: Amended charter to effect a 1-for-10 reverse stock split of common stock, effective May 21, 2026 (effective 2026-05-21).","evidence_excerpt":"On May 20, 2026, the Company expects to file an amendment to its Charter with the Secretary of State of the State of Delaware (the “Amendment”) to effect the Reverse Stock Split.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-058997","anchor_url":"https://secwatch.observer/filing/0001213900-26-058997#claim-eac92f135eb0603e05a1fff2a3f784adef65beea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026058997/0001213900-26-058997-index.htm"},{"fact_type":"shareholder_vote","fact_key":"861025390c1f1b99cad5412ad377ad7ebda5023d","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-04-30","outcome":"passed","proposal_text":"Approval of the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal.","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"1,530","votes_against":"223,071","votes_for":"1,332,088","votes_withheld":null}]},"claim":"Onconetix, Inc. shareholders approved Approval of the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal. at the 2026-04-30 meeting.","evidence_excerpt":"2. The Adjournment Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 1,332,088 223,071 1,530","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-051575","anchor_url":"https://secwatch.observer/filing/0001213900-26-051575#claim-861025390c1f1b99cad5412ad377ad7ebda5023d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026051575/0001213900-26-051575-index.htm"},{"fact_type":"shareholder_vote","fact_key":"67528a6432e915e4366ea9f60ad33179bb338f1f","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-04-30","outcome":"passed","proposal_text":"Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of all of the outstanding shares of the Company's common stock, par value $0.00001 per share, at a ratio in the range of 1-for-2 to 1-for-10, at any time prior to th","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"1,393","votes_against":"253,378","votes_for":"1,301,918","votes_withheld":null}]},"claim":"Onconetix, Inc. shareholders approved Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of all of the outstanding shares of the Company's common stock, par value $0.00001 per share, at a ratio in the range of 1-for-2 to 1-for-10, at any time prior to th at the 2026-04-30 meeting.","evidence_excerpt":"1. Reverse Stock Split Proposal The votes were cast for this matter as follows: Votes For Votes Against Abstentions 1,301,918 253,378 1,393","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-051575","anchor_url":"https://secwatch.observer/filing/0001213900-26-051575#claim-67528a6432e915e4366ea9f60ad33179bb338f1f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026051575/0001213900-26-051575-index.htm"},{"fact_type":"governance_change","fact_key":"22bbb8be6740fe0ae96916737c35f1e075709ad3","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2026-03-27T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-25","item_codes_triggered":["5.03"],"summary_text":"Onconetix, Inc. filed an amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-5 reverse stock split, effective March 25, 2026."},"claim":"Onconetix, Inc.: Onconetix, Inc. filed an amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-5 reverse stock split, effective March 25, 2026 (effective 2026-03-25).","evidence_excerpt":"On March 24, 2026, the Company filed the Amendment to its Charter with the Secretary of State of the State of Delaware to effect the Reverse Stock Split.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-034902","anchor_url":"https://secwatch.observer/filing/0001213900-26-034902#claim-22bbb8be6740fe0ae96916737c35f1e075709ad3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026034902/0001213900-26-034902-index.htm"},{"fact_type":"material_agreement","fact_key":"e6f9f060c6115e4ce05589769e2f3db0344b5176","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Share Exchange Agreement","agreement_type":"merger","counterparty":"Realbotix Corp., Simulacra Corporation, and Realbotix, LLC","effective_date":"2026-02-11","item_codes_triggered":["1.01"],"value_text":null},"claim":"Onconetix, Inc. entered into Share Exchange Agreement with Realbotix Corp., Simulacra Corporation, and Realbotix, LLC (effective 2026-02-11).","evidence_excerpt":"On February 11, 2026, Onconetix, Inc, a Delaware corporation (“ Onconetix ” or “ Buyer ”), entered into a Share Exchange Agreement (the “ Share Exchange Agreement ”), by and among (i) Onconetix, (ii) Realbotix Corp., a company existing under the laws of the Province of Ontario (“ Parent ”), (iii) Simulacra Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (the “ Seller ”) and (iv) Realbotix, LLC, a Delaware limited liability company and wholly owned subsidiary of the Seller (the “ Company ” or “ Realbotix ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-015212","anchor_url":"https://secwatch.observer/filing/0001213900-26-015212#claim-e6f9f060c6115e4ce05589769e2f3db0344b5176","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026015212/0001213900-26-015212-index.htm"},{"fact_type":"material_agreement","fact_key":"8c0c6676c7fbe639650e472c05a2d0e0ab1cf1d8","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-12-10T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment","agreement_type":"license","counterparty":"Laboratory Corporation of America Holdings (Labcorp)","effective_date":"2025-12-06","item_codes_triggered":["1.01"],"value_text":null},"claim":"Onconetix, Inc. amended Amendment with Laboratory Corporation of America Holdings (Labcorp) (effective 2025-12-06).","evidence_excerpt":"On December 6, 2025, Proteomedix AG, a Swiss Company (“Proteomedix”), a wholly-owned subsiairy of Onconetix, Inc. (the “Company”), entered into an amendment (the “Amendment”) of the license agreement with Laboratory Corporation of America Holdings (“Labcorp”) dated as of March 27, 2023, by and between the Company and Labcorp (the “Agreement”), pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products developed by Labcorp using Proteomedix’s intellectual property covered by the license in the United States (the “Licensed Products”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-119898","anchor_url":"https://secwatch.observer/filing/0001213900-25-119898#claim-8c0c6676c7fbe639650e472c05a2d0e0ab1cf1d8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025119898/0001213900-25-119898-index.htm"},{"fact_type":"equity_issuance","fact_key":"82b7188a7bf9c7aa8a6488d81e243c87787ad65f","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-10-03T23:59:59+00:00","payload":{"action":"pipe","consideration_text":"aggregate purchase price of approximately $6.25 million","effective_date":"2025-10-01","item_codes_triggered":["3.02"],"purchaser":"institutional investors","security_type":"warrant","shares_text":"warrants to purchase 2,025,223 shares of Common Stock"},"claim":"Onconetix, Inc. issued warrants to purchase 2,025,223 shares of Common Stock of warrant to institutional investors for aggregate purchase price of approximately $6.25 million.","evidence_excerpt":"On October 1, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (“ Series E Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”) and warrants to purchase 2,025,223 shares of Common Stock (the “ Warrants ” and, together with the Series E Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $6.25 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-095847","anchor_url":"https://secwatch.observer/filing/0001213900-25-095847#claim-82b7188a7bf9c7aa8a6488d81e243c87787ad65f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025095847/0001213900-25-095847-index.htm"},{"fact_type":"equity_issuance","fact_key":"f3f54d7bb526dba407a29fd1f6025fd856007c83","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-10-03T23:59:59+00:00","payload":{"action":"pipe","consideration_text":"aggregate purchase price of approximately $6.25 million","effective_date":"2025-10-01","item_codes_triggered":["3.02"],"purchaser":"institutional investors","security_type":"preferred_stock","shares_text":"7,813 shares of Series E convertible preferred stock"},"claim":"Onconetix, Inc. issued 7,813 shares of Series E convertible preferred stock of preferred stock to institutional investors for aggregate purchase price of approximately $6.25 million.","evidence_excerpt":"On October 1, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (“ Series E Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”) and warrants to purchase 2,025,223 shares of Common Stock (the “ Warrants ” and, together with the Series E Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $6.25 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-095847","anchor_url":"https://secwatch.observer/filing/0001213900-25-095847#claim-f3f54d7bb526dba407a29fd1f6025fd856007c83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025095847/0001213900-25-095847-index.htm"},{"fact_type":"equity_issuance","fact_key":"36757545cbc78a1f86ae0504a0f3c9e445c43025","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-09-26T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"included in aggregate purchase price of approximately $12.9 million","effective_date":"2025-09-22","item_codes_triggered":["3.02"],"purchaser":"eleven institutional investors","security_type":"warrant","shares_text":"warrants to purchase 4,362,827 shares of Common Stock"},"claim":"Onconetix, Inc. issued warrants to purchase 4,362,827 shares of Common Stock of warrant to eleven institutional investors for included in aggregate purchase price of approximately $12.9 million.","evidence_excerpt":"On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001213900-25-091966","anchor_url":"https://secwatch.observer/filing/0001213900-25-091966#claim-36757545cbc78a1f86ae0504a0f3c9e445c43025","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025091966/0001213900-25-091966-index.htm"},{"fact_type":"equity_issuance","fact_key":"5a7ae56c546fd95acdf972a67614b3ae0b38c4da","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-09-26T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate purchase price of approximately $12.9 million of which approximately $9.3 million was paid in cash and the balance was used to offset certain amounts","effective_date":"2025-09-22","item_codes_triggered":["3.02"],"purchaser":"eleven institutional investors","security_type":"preferred_stock","shares_text":"16,099 shares of Series D convertible preferred stock"},"claim":"Onconetix, Inc. issued 16,099 shares of Series D convertible preferred stock of preferred stock to eleven institutional investors for aggregate purchase price of approximately $12.9 million of which approximately $9.3 million was paid in cash and the balance was used to offset certain amounts.","evidence_excerpt":"On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001213900-25-091966","anchor_url":"https://secwatch.observer/filing/0001213900-25-091966#claim-5a7ae56c546fd95acdf972a67614b3ae0b38c4da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025091966/0001213900-25-091966-index.htm"},{"fact_type":"debt_financing","fact_key":"fb0e86a0798b5fa87cfe4891967af53af7fa298c","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-09-04T23:59:59+00:00","payload":{"counterparty":"Veru Inc.","effective_date":"2025-08-28","event":"amendment","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"September 19, 2025","principal_text":"aggregate principal amount of $5.2 million"},"claim":"Onconetix, Inc. amended loan of aggregate principal amount of $5.2 million with Veru Inc. maturing September 19, 2025.","evidence_excerpt":"On August 28, 2025, Veru and the Company agreed to amend and restate the September Veru Note (as amended and restated, the “ Second A&R September Veru Note ”). Pursuant to the Second A&R September Veru Note, the principal amount owed to Veru was increased by $100,000 to an aggregate principal amount of $5.2 million, and the maturity date was amended to September 19, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-084500","anchor_url":"https://secwatch.observer/filing/0001213900-25-084500#claim-fb0e86a0798b5fa87cfe4891967af53af7fa298c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025084500/0001213900-25-084500-index.htm"},{"fact_type":"debt_financing","fact_key":"8d17638de0b58cc45e7103b75cdb008b96af8a9e","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-09-04T23:59:59+00:00","payload":{"counterparty":"KCP Fund I, LLC","effective_date":"2025-08-28","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone ... and (ii) May 28, 2026","principal_text":"principal amount of $58,823.53"},"claim":"Onconetix, Inc. incurred loan of principal amount of $58,823.53 with KCP Fund I, LLC maturing upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone ... and (ii) May 28, 2026.","evidence_excerpt":"(ii) KCP Fund I, LLC, an affiliate of Keystone (the “ KCP Note ”, and together with the Keystone Note, the “ Notes ”) each with original issue discount of $8,823.53 and a principal amount of $58,823.53","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-084500","anchor_url":"https://secwatch.observer/filing/0001213900-25-084500#claim-8d17638de0b58cc45e7103b75cdb008b96af8a9e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025084500/0001213900-25-084500-index.htm"},{"fact_type":"debt_financing","fact_key":"9ca87da0817adc90d6995b9706755f09ec9db3b4","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-09-04T23:59:59+00:00","payload":{"counterparty":"Keystone Capital Partners, LLC","effective_date":"2025-08-28","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone ... and (ii) May 28, 2026","principal_text":"principal amount of $58,823.53"},"claim":"Onconetix, Inc. incurred loan of principal amount of $58,823.53 with Keystone Capital Partners, LLC maturing upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone ... and (ii) May 28, 2026.","evidence_excerpt":"I, LLC, an affiliate of Keystone (the “ KCP Note ”,\nand together with the Keystone Note, the “ Notes ”) each with original issue discount of $8,823.53 and a principal amount\nof $58,823.53. The Notes are due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from its equity\nline of credit with Keystone (the “ ELOC ”) and (ii) May 28,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-084500","anchor_url":"https://secwatch.observer/filing/0001213900-25-084500#claim-9ca87da0817adc90d6995b9706755f09ec9db3b4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025084500/0001213900-25-084500-index.htm"},{"fact_type":"debt_financing","fact_key":"5b83149ff3076521d093d38640fb70ec6bd3ddfa","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-08-12T23:59:59+00:00","payload":{"counterparty":"Veru Inc.","effective_date":"2025-08-07","event":"amendment","instrument_type":"other","interest_rate_text":"non-interest bearing","item_codes_triggered":["2.03"],"maturity_text":"maturity date was amended to August 14, 2025","principal_text":"principal amount owed to Veru was increased by $100,000 to an aggregate principal amount of $5.1 million"},"claim":"Onconetix, Inc. amended debt of principal amount owed to Veru was increased by $100,000 to an aggregate principal amount of $5.1 million with Veru Inc. at non-interest bearing maturing maturity date was amended to August 14, 2025.","evidence_excerpt":"the September Veru Note (as amended and restated, the “ A&R September Veru Note ”).\nPursuant to the A&R September Veru Note, the principal amount owed to Veru was increased by $100,000 to an aggregate principal amount\nof $5.1 million, and the maturity date was amended to August 14, 2025. All other terms of the September Veru Note remained the same. The above","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-074952","anchor_url":"https://secwatch.observer/filing/0001213900-25-074952#claim-5b83149ff3076521d093d38640fb70ec6bd3ddfa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025074952/0001213900-25-074952-index.htm"},{"fact_type":"debt_financing","fact_key":"1c0de1b22cad55c0f80556ecc8ee91c568025bbc","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-08-12T23:59:59+00:00","payload":{"counterparty":"Keystone Capital Partners, LLC","effective_date":"2025-08-06","event":"incurrence","instrument_type":"loan","interest_rate_text":"does not initially bear interest...any amounts due which are not paid when due s","item_codes_triggered":["2.03"],"maturity_text":"due and payable upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone and (ii) March 6, 2026","principal_text":"aggregate principal amount of $117,647.06"},"claim":"Onconetix, Inc. incurred loan of aggregate principal amount of $117,647.06 with Keystone Capital Partners, LLC at does not initially bear interest...any amounts due which are not paid when due s maturing due and payable upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone and (ii) March 6, 2026.","evidence_excerpt":"On August 6, 2025, Onconetix, Inc. (the “ Company ”) issued a promissory note (the “ Keystone Note” ) to Keystone Capital Partners, LLC (“ Keystone ”) with original issue discount of $17,647.06, in an aggregate principal amount of $117,647.06.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-074952","anchor_url":"https://secwatch.observer/filing/0001213900-25-074952#claim-1c0de1b22cad55c0f80556ecc8ee91c568025bbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025074952/0001213900-25-074952-index.htm"},{"fact_type":"debt_financing","fact_key":"192822e1dd9dd4758209d516d7f2b946ee636dc1","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-06-11T23:59:59+00:00","payload":{"counterparty":"Keystone Capital Partners, LLC","effective_date":"2025-06-05","event":"incurrence","instrument_type":"loan","interest_rate_text":"does not initially bear interest","item_codes_triggered":["2.03"],"maturity_text":"March 5, 2026","principal_text":"aggregate principal amount of $147,058.82"},"claim":"Onconetix, Inc. incurred loan of aggregate principal amount of $147,058.82 with Keystone Capital Partners, LLC at does not initially bear interest maturing March 5, 2026.","evidence_excerpt":"issued a promissory note to Keystone Capital Partners, LLC with original issue discount of $22,058.82, in an aggregate principal amount of $147,058.82. The note is due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from the ELOC and (ii) March 5, 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-053367","anchor_url":"https://secwatch.observer/filing/0001213900-25-053367#claim-192822e1dd9dd4758209d516d7f2b946ee636dc1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025053367/0001213900-25-053367-index.htm"},{"fact_type":"governance_change","fact_key":"05bf923994ad0f2c063579fe65b307cbb088de02","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-06-11T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-85 reverse stock split"},"claim":"Onconetix, Inc.: Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-85 reverse stock split (effective 2025-06-13).","evidence_excerpt":"On June 11, 2025, the Company expects to file the Amendment to its Charter with the Secretary of State of the State of Delaware to effect a reverse stock split of its Common Stock at a ratio of 1-to-85 (the \"Reverse Stock Split\"). The Reverse Stock Split will become effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on June 13, 2025 (the \"Effective Time\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-053367","anchor_url":"https://secwatch.observer/filing/0001213900-25-053367#claim-05bf923994ad0f2c063579fe65b307cbb088de02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025053367/0001213900-25-053367-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"bf88284493228d69bf7513cd53cf73fe225b621a","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-05-22T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-05-20","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"May 20, 2025, Onconetix,\nInc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC\n(“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing\nRules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its Quarterly Report on Form\n10-Q for the three months ended March 31, 2025 (the “ 10-Q ”), and that this matter serves as an additional basis for\ndelisting the Company’s securities from Nasdaq. As previously reported in\nthe Current Report on Form 8-K filed with the Secur","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001213900-25-046909","anchor_url":"https://secwatch.observer/filing/0001213900-25-046909#claim-bf88284493228d69bf7513cd53cf73fe225b621a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025046909/0001213900-25-046909-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"0a82ae633c73403be3515caa48ad83c950b42a83","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-04-30T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":"2025-05-01","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-04-24","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"April 24, 2025, Onconetix,\nInc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC\n(“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing\nRules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2024 (the “ 10-K ”), and that this matter serves as an additional basis for delisting\nthe Company’s securities from Nasdaq. As previously reported in\nthe Current Report on Form 8-K filed with the Secu","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-037765","anchor_url":"https://secwatch.observer/filing/0001213900-25-037765#claim-0a82ae633c73403be3515caa48ad83c950b42a83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025037765/0001213900-25-037765-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c64ae4496f552b580a080415015f2143642a7317","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-04-18T23:59:59+00:00","payload":{"company_response":"intends to request a hearing","compliance_status":"deficient","cure_deadline":"2025-04-23","deficiency_type":"minimum_bid_price","delisting_effective_date":"2025-04-23","exchange":"nasdaq","hearing_date":"requested","immediate_listing_effect":null,"minimum_requirement":"$1.00","notice_date":"2025-04-14","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)","5810(c)(3)(A)(iii)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).","evidence_excerpt":"April 14, 2025, Nasdaq\nissued a further notice (the “Notice”) to the Company that it determined that the Company’s securities had a closing\nbid price of $0.10 or less for ten consecutive trading days. Accordingly, the Company is subject to the provisions under Nasdaq Listing\nRule 5810(c)(3)(A)(iii). As a result, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”),\ntrading of the Common Stock will be suspended at the opening of business on April 23, 2025, and a Form 25-NSE will be filed with the Commission,\nwhich will remove the Company’s securities from","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-033295","anchor_url":"https://secwatch.observer/filing/0001213900-25-033295#claim-c64ae4496f552b580a080415015f2143642a7317","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025033295/0001213900-25-033295-index.htm"},{"fact_type":"executive_change","fact_key":"3487da2128","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-04-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-02","interim":true,"role":"Interim Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Karina Fedasz was appointed as Interim Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"On April 2, 2025, the Company appointed Karina Fedasz, 52, the Company’s Interim Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-028646","anchor_url":"https://secwatch.observer/filing/0001213900-25-028646#claim-3487da2128","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025028646/0001213900-25-028646-index.htm"},{"fact_type":"executive_change","fact_key":"b81dbaf96e","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-04-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-28","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"James Sapirstein resigned as Executive Chairman at Onconetix, Inc..","evidence_excerpt":"Effective as of March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-028646","anchor_url":"https://secwatch.observer/filing/0001213900-25-028646#claim-b81dbaf96e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025028646/0001213900-25-028646-index.htm"},{"fact_type":"executive_change","fact_key":"8409c7cea4","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-02-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-24","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrew Oakley was appointed as Class II director at Onconetix, Inc..","evidence_excerpt":"On February 24, 2025, the Board approved an increase to the Board’s size from five to six members and appointed Andrew Oakley, 62, to fill the new Board seat as a Class II director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-018867","anchor_url":"https://secwatch.observer/filing/0001213900-25-018867#claim-8409c7cea4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm"},{"fact_type":"executive_change","fact_key":"94076bf8cc","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-02-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-24","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"James Sapirstein was appointed as Executive Chairman at Onconetix, Inc..","evidence_excerpt":"On February 24, 2025, the Company’s Board of Directors (the “Board”) appointed James Sapirstein, 63, an existing member of the Board, as Executive Chairman.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-018867","anchor_url":"https://secwatch.observer/filing/0001213900-25-018867#claim-94076bf8cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm"},{"fact_type":"executive_change","fact_key":"b14b1b6922","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-02-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Interim Chief Executive Officer and Chief Science Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Ralph Schiess resigned as Interim Chief Executive Officer and Chief Science Officer at Onconetix, Inc..","evidence_excerpt":"On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-018867","anchor_url":"https://secwatch.observer/filing/0001213900-25-018867#claim-b14b1b6922","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm"},{"fact_type":"executive_change","fact_key":"07911a7a76","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-02-18T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-18","interim":false,"role":"Chief Strategy Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Christian Brühlmann resigned as Chief Strategy Officer at Onconetix, Inc..","evidence_excerpt":"On February 18, 2025, Christian Brühlmann resigned from his position as Chief Strategy Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-014928","anchor_url":"https://secwatch.observer/filing/0001213900-25-014928#claim-07911a7a76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025014928/0001213900-25-014928-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"7d18fd0bf02930681618d9f504a25a7c1aa66880","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-01-24T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-07-22","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-01-23","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"January 23, 2025, Onconetix,\nInc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”)\nindicating that, based upon the closing bid price of the Company’s common stock, par value $0.00001 per share (“Common Stock”),\nfrom November 25, 2024 to January 10, 2025, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq\nCapital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate\neffect on the continued li","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-006553","anchor_url":"https://secwatch.observer/filing/0001213900-25-006553#claim-7d18fd0bf02930681618d9f504a25a7c1aa66880","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025006553/0001213900-25-006553-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"7d18fd0bf02930681618d9f504a25a7c1aa66880","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2025-01-24T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-07-22","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-01-23","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"]},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"January 23, 2025, Onconetix,\nInc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”)\nindicating that, based upon the closing bid price of the Company’s commo","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-006553","anchor_url":"https://secwatch.observer/filing/0001213900-25-006553#claim-7d18fd0bf02930681618d9f504a25a7c1aa66880","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025006553/0001213900-25-006553-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"1b4987c6c72979546018a3e007b5a1eb4bae1aae","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-12-12T23:59:59+00:00","payload":{"company_response":"On December 10, 2024, the Company filed its Form 10-Q.","compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-12-06","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"December 6, 2024, Onconetix, Inc. (the “Company”)\nreceived a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that, as a result of not\nhaving timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”) with the Securities\nand Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires\nlisted companies to timely file all required periodic financial reports with the SEC. On December 10, 2024, the Company filed its Form 10-Q with the SEC. This Cur","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-108439","anchor_url":"https://secwatch.observer/filing/0001213900-24-108439#claim-1b4987c6c72979546018a3e007b5a1eb4bae1aae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024108439/0001213900-24-108439-index.htm"},{"fact_type":"auditor_change","fact_key":"767df9c82909815ad28454bd0912c956509453ea","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-10-21T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"EisnerAmper LLP","disagreement_text":null,"effective_date":"2024-10-15","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"EisnerAmper LLP resigned as auditor of Onconetix, Inc..","evidence_excerpt":"On October 15, 2024, EisnerAmper LLP (“EA”) submitted its resignation as Onconetix, Inc.’s (the “Company”) independent registered public accounting firm, effective upon the Company’s upcoming filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-089338","anchor_url":"https://secwatch.observer/filing/0001213900-24-089338#claim-767df9c82909815ad28454bd0912c956509453ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024089338/0001213900-24-089338-index.htm"},{"fact_type":"governance_change","fact_key":"a4ff2a5ca1cd8fc5c2a212d5deafa09866181f16","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-10-09T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-09-24","item_codes_triggered":["5.03"],"summary_text":"Amended Certificate of Incorporation to effect a 1-for-40 reverse stock split of common stock"},"claim":"Onconetix, Inc.: Amended Certificate of Incorporation to effect a 1-for-40 reverse stock split of common stock (effective 2024-09-24).","evidence_excerpt":"On September 23, 2024, the Company filed an amendment (the “ Amendment ”) to the Company’s Amended and Restated Certificate of Incorporation to effect a Reverse Stock Split of all of the outstanding shares of its issued and outstanding Common Stock at a ratio of one-for-forty (1:40). The Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on September 24, 2024 (the “ Effective Time ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-086655","anchor_url":"https://secwatch.observer/filing/0001213900-24-086655#claim-a4ff2a5ca1cd8fc5c2a212d5deafa09866181f16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024086655/0001213900-24-086655-index.htm"},{"fact_type":"executive_change","fact_key":"0c467e765e","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-06-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-10","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Karina Fedasz was appointed as Interim Chief Financial Officer at Onconetix, Inc..","evidence_excerpt":"In connection with Ms. Fedasz’s appointment as Interim Chief Financial Officer, on June 10, 2024, the Company and Ms. Fedasz entered into a consulting agreement (the “ Fedasz Consulting Agreement ”), pursuant to which Ms. Fedasz will serve as Interim Chief Financial Officer of the Company and will be paid $15,000 per month for up to 80 hours of monthly service to the Company and will provide signatory services for $2,500 per month.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-052976","anchor_url":"https://secwatch.observer/filing/0001213900-24-052976#claim-0c467e765e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024052976/0001213900-24-052976-index.htm"},{"fact_type":"executive_change","fact_key":"657f5834f2","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-10","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Karina M. Fedasz was appointed as Interim Chief Financial Officer at Onconetix, Inc..","evidence_excerpt":"On June 10, 2024, the Company appointed Karina M. Fedasz, 51, as Interim Chief Financial Officer of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-052469","anchor_url":"https://secwatch.observer/filing/0001213900-24-052469#claim-657f5834f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/0001213900-24-052469-index.htm"},{"fact_type":"executive_change","fact_key":"ded773d61f","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-08","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Karina M. Fedasz","successor_named":true},"claim":"Bruce Harmon resigned as Chief Financial Officer at Onconetix, Inc..","evidence_excerpt":"On June 8, 2024, Bruce Harmon resigned as Chief Financial Officer of Onconetix, Inc. (the “ Company ”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-052469","anchor_url":"https://secwatch.observer/filing/0001213900-24-052469#claim-ded773d61f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/0001213900-24-052469-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c61eeb54f0887518630dd3a4e67c2b90721a2adc","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-06-24","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$2,500,000 stockholders' equity","notice_date":"2024-05-08","notice_type":"deficiency_notice","plan_due_date":"2024-06-24","raw_rule_text":"Listing Rule 5550(b)(1)","reported_value":"$1,404,476","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"equity for\nthe fiscal year ended December 31, 2023 as reported in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange\nCommission on April 1, 2024 was $1,404,476, and as of the date of the Notice, the Company did not meet the alternatives to the Minimum\nStockholders’ Equity Requirement of having either (i) a market value of listed","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-042369","anchor_url":"https://secwatch.observer/filing/0001213900-24-042369#claim-c61eeb54f0887518630dd3a4e67c2b90721a2adc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024042369/0001213900-24-042369-index.htm"},{"fact_type":"material_agreement","fact_key":"5a64cdab5ab466d28c4caded4954f5ae3d4ee634","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Altos Amendment","agreement_type":"equity_purchase","counterparty":"Altos Ventures","effective_date":"2024-04-24","item_codes_triggered":["1.01"],"value_text":null},"claim":"Onconetix, Inc. amended Altos Amendment with Altos Ventures (effective 2024-04-24).","evidence_excerpt":"On April 24, 2024, the Debenture was amended to extend the maturity date to the earlier of (i) the closing under the Subscription Agreement and (ii) October 31, 2024 (the \"Altos Amendment\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-036645","anchor_url":"https://secwatch.observer/filing/0001213900-24-036645#claim-5a64cdab5ab466d28c4caded4954f5ae3d4ee634","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/0001213900-24-036645-index.htm"},{"fact_type":"material_agreement","fact_key":"9a97d2ba4e7face99e2c195309b1a687a2e02dfb","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Forbearance Agreement","agreement_type":"other","counterparty":"Veru Inc.","effective_date":"2024-04-24","item_codes_triggered":["1.01"],"value_text":null},"claim":"Onconetix, Inc. entered into Forbearance Agreement with Veru Inc. (effective 2024-04-24).","evidence_excerpt":"(the “Company”) entered into an asset purchase agreement with Veru Inc., a Wisconsin\ncorporation (“Veru”) (the “Veru APA”). Pursuant to the terms of the Veru APA, the Company agreed to provide Veru","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-036645","anchor_url":"https://secwatch.observer/filing/0001213900-24-036645#claim-9a97d2ba4e7face99e2c195309b1a687a2e02dfb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/0001213900-24-036645-index.htm"},{"fact_type":"ma_transaction","fact_key":"383aab547004759bc01765eff86dca81586bdfbc","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-12-15","consideration_text":"share exchange","counterparty":"Proteomedix AG","effective_date":"2023-12-15","item_codes_triggered":["2.01"]},"claim":"Onconetix, Inc. completed an acquisition involving Proteomedix AG for share exchange (closed 2023-12-15).","evidence_excerpt":"the Company consummated a share exchange transaction (the “ Share Exchange ”) with Proteomedix on December 15, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-017544","anchor_url":"https://secwatch.observer/filing/0001213900-24-017544#claim-383aab547004759bc01765eff86dca81586bdfbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/0001213900-24-017544-index.htm"},{"fact_type":"executive_change","fact_key":"386aad2c51","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-02-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ajit Singh was appointed as Director at Onconetix, Inc..","evidence_excerpt":"On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-012876","anchor_url":"https://secwatch.observer/filing/0001213900-24-012876#claim-386aad2c51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024012876/0001213900-24-012876-index.htm"},{"fact_type":"executive_change","fact_key":"6e46e16c49","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-02-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":"Ajit Singh","successor_named":true},"claim":"Neil Campbell resigned as Director at Onconetix, Inc..","evidence_excerpt":"On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-012876","anchor_url":"https://secwatch.observer/filing/0001213900-24-012876#claim-6e46e16c49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024012876/0001213900-24-012876-index.htm"},{"fact_type":"executive_change","fact_key":"ba5798cc0c","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-06","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Thomas Meier was appointed as Director at Onconetix, Inc..","evidence_excerpt":"On February 6, 2024, pursuant to the Certificate of Designation of Series B Convertible Preferred Stock, the holders of Series B Convertible Preferred Stock appointed Thomas Meier, PhD, to the board of directors of Onconetix, Inc. (the “ Company ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-012608","anchor_url":"https://secwatch.observer/filing/0001213900-24-012608#claim-ba5798cc0c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/0001213900-24-012608-index.htm"},{"fact_type":"executive_change","fact_key":"30e97a4ace","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-12-21","interim":false,"role":"Chief Business Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Erin Henderson resigned as Chief Business Officer at Onconetix, Inc..","evidence_excerpt":"Erin Henderson resigned as Chief Business Officer of Onconetix, Inc. (the “Company”), effective as of December 21, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-004855","anchor_url":"https://secwatch.observer/filing/0001213900-24-004855#claim-30e97a4ace","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024004855/0001213900-24-004855-index.htm"},{"fact_type":"executive_change","fact_key":"44412208c3","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-01-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-12","interim":false,"role":"Lead Independent Director","role_category":"other","successor_name":null,"successor_named":false},"claim":"James Sapirstein was appointed as Lead Independent Director at Onconetix, Inc..","evidence_excerpt":"Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board’s appointment of a permanent chief executive officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-003413","anchor_url":"https://secwatch.observer/filing/0001213900-24-003413#claim-44412208c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm"},{"fact_type":"executive_change","fact_key":"b80e0e56d2","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-01-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-12","interim":true,"role":"Interim Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Dr. Ralph Schiess was appointed as Interim Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company’s Chief Science Officer, to serve as the Company’s Interim Chief Executive Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-003413","anchor_url":"https://secwatch.observer/filing/0001213900-24-003413#claim-b80e0e56d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm"},{"fact_type":"executive_change","fact_key":"326b80a204","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2024-01-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-01-10","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Dr. Ralph Schiess","successor_named":true},"claim":"Dr. Neil Campbell resigned as President and Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-003413","anchor_url":"https://secwatch.observer/filing/0001213900-24-003413#claim-326b80a204","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm"},{"fact_type":"executive_change","fact_key":"64f5832295","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-12-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-12-21","interim":false,"role":"Chief Business Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Erin Henderson resigned as Chief Business Officer at Onconetix, Inc..","evidence_excerpt":"On and effective December 21, 2023, Erin Henderson resigned as Chief Business Officer of Onconetix, Inc. (the “Company”) to pursue other opportunities.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-23-099224","anchor_url":"https://secwatch.observer/filing/0001213900-23-099224#claim-64f5832295","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023099224/0001213900-23-099224-index.htm"},{"fact_type":"material_agreement","fact_key":"106c9b74b91720bf3b67be7b6bad0504f6362298","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-12-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Share Exchange Agreement","agreement_type":"merger","counterparty":"Proteomedix AG","effective_date":"2023-12-15","item_codes_triggered":["1.01"],"value_text":"Aggregate value of Exchange Shares at Closing approximately $75,000,000; Onconetix issued 3,675,414"},"claim":"Onconetix, Inc. entered into Share Exchange Agreement with Proteomedix AG valued at Aggregate value of Exchange Shares at Closing approximately $75,000,000; Onconetix issued 3,675,414 (effective 2023-12-15).","evidence_excerpt":"On December 15, 2023, Onconetix, Inc, a Delaware corporation f/k/a Blue Water Biotech, Inc. (“ Onconetix ” or the “ Buyer ”), entered into a Share Exchange Agreement","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-098928","anchor_url":"https://secwatch.observer/filing/0001213900-23-098928#claim-106c9b74b91720bf3b67be7b6bad0504f6362298","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023098928/0001213900-23-098928-index.htm"},{"fact_type":"governance_change","fact_key":"3d75798d3a562c64667cf0ed546d01e9d406eb99","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-12-21T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-12-15","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to reflect the name change to Onconetix, Inc."},"claim":"Onconetix, Inc.: Amended bylaws to reflect the name change to Onconetix, Inc (effective 2023-12-15).","evidence_excerpt":"On December 1, 2023, the Board approved the Name Change and an amendment to the Company’s bylaws to reflect the Name Change, effective as of the Closing Date on December 15, 2023. No other changes were made to the bylaws.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-097738","anchor_url":"https://secwatch.observer/filing/0001213900-23-097738#claim-3d75798d3a562c64667cf0ed546d01e9d406eb99","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm"},{"fact_type":"governance_change","fact_key":"f80ca002cc448361bc232db67473db9dd7dfafe0","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-12-21T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-12-15","item_codes_triggered":["5.03"],"summary_text":"Amended articles of incorporation to change company name from Blue Water Biotech, Inc. to Onconetix, Inc."},"claim":"Onconetix, Inc.: Amended articles of incorporation to change company name from Blue Water Biotech, Inc. to Onconetix, Inc (effective 2023-12-15).","evidence_excerpt":"On December 15, 2023, Onconetix filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Delaware Secretary of State (the “ Amendment ”). The Amendment changed the name of Onconetix from “Blue Water Biotech, Inc.” to “Onconetix, Inc.,” effective immediately (the “ Name Change ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-097738","anchor_url":"https://secwatch.observer/filing/0001213900-23-097738#claim-f80ca002cc448361bc232db67473db9dd7dfafe0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm"},{"fact_type":"material_agreement","fact_key":"524ebb796b9c98c3e8824a9233fb38e5be6fb4ea","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-12-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Share Exchange Agreement","agreement_type":"merger","counterparty":"Proteomedix AG, the Sellers, and the Sellers’ Representative","effective_date":"2023-12-15","item_codes_triggered":["1.01"],"value_text":"$75,000,000"},"claim":"Onconetix, Inc. entered into Share Exchange Agreement with Proteomedix AG, the Sellers, and the Sellers’ Representative valued at $75,000,000 (effective 2023-12-15).","evidence_excerpt":"On December 15, 2023, Onconetix, Inc, a Delaware corporation f/k/a Blue Water Biotech, Inc. (“ Onconetix ” or the “ Buyer ”), entered into a Share Exchange Agreement (the “ Share Exchange Agreement ”), by and among (i) Onconetix, (ii) Proteomedix AG, a Swiss Company (“ Proteomedix ” or the “ Company ”), (iii) each of the holders of outstanding capital stock or Company Convertible Securities (other than Company Stock Options) named therein (collectively, the “ Sellers ”) and (iv) Thomas Meier, in the capacity as the representative of Sellers in accordance with the terms and conditions of the Share Exchange Agreement (the “ Sellers’ Representative ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-097738","anchor_url":"https://secwatch.observer/filing/0001213900-23-097738#claim-524ebb796b9c98c3e8824a9233fb38e5be6fb4ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm"},{"fact_type":"executive_change","fact_key":"5869580371","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-12-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-12-15","interim":false,"role":"Chief Science Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Ralph Schiess was appointed as Chief Science Officer at Onconetix, Inc..","evidence_excerpt":"On December 15, 2023, Onconetix appointed Ralph Schiess, 45, as Chief Science Officer of Onconetix, effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-097738","anchor_url":"https://secwatch.observer/filing/0001213900-23-097738#claim-5869580371","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm"},{"fact_type":"executive_change","fact_key":"53b2b900a5","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-12-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-12-15","interim":false,"role":"Chief Strategy Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Christian Brühlmann was appointed as Chief Strategy Officer at Onconetix, Inc..","evidence_excerpt":"On December 15, 2023, Onconetix appointed Christian Brühlmann, 47, as Chief Strategy Officer of Onconetix, effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-097738","anchor_url":"https://secwatch.observer/filing/0001213900-23-097738#claim-53b2b900a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm"},{"fact_type":"executive_change","fact_key":"745f5983d0","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-10-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-10-04","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jon Garfield resigned as Chief Financial Officer at Onconetix, Inc..","evidence_excerpt":"Effective as of October 4, 2023, Jon Garfield resigned as Chief Financial Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-081324","anchor_url":"https://secwatch.observer/filing/0001213900-23-081324#claim-745f5983d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm"},{"fact_type":"executive_change","fact_key":"f0709191e4","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-10-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-04","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Neil Campbell was appointed as President and Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"appointed Dr. Neil Campbell, 63, as President and Chief Executive Officer of the Company and as a member of the Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-081324","anchor_url":"https://secwatch.observer/filing/0001213900-23-081324#claim-f0709191e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm"},{"fact_type":"material_agreement","fact_key":"217f8400154fbe096ae0072f592381a83adc1f8d","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-10-03T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Asset Purchase Agreement with Veru Inc.","agreement_type":"asset_purchase","counterparty":"Veru Inc.","effective_date":"2023-09-29","item_codes_triggered":["1.01"],"value_text":"Amendment of $4 million installment payment to $1 million cash plus issuance of 3,000 shares of Seri"},"claim":"Onconetix, Inc. amended Amendment to Asset Purchase Agreement with Veru Inc. with Veru Inc. valued at Amendment of $4 million installment payment to $1 million cash plus issuance of 3,000 shares of Seri (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, the Company entered into an Amendment (the \"Amendment\") of the Asset Purchase Agreement (the \"Purchase Agreement\"), dated as of April 19, 2023, by and between the Company and Veru Inc., a Wisconsin corporation (\"Veru\") relating to the sale of the product ENTADFI TM .","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001013762-23-000742","anchor_url":"https://secwatch.observer/filing/0001013762-23-000742#claim-217f8400154fbe096ae0072f592381a83adc1f8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/0001013762-23-000742-index.htm"},{"fact_type":"material_agreement","fact_key":"07040c791f7ce2229e271daf7e39db1106609a34","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-10-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Exclusive Distribution Agreement","agreement_type":"supply","counterparty":"Cardinal Health 105, LLC","effective_date":"2023-09-20","item_codes_triggered":["1.01"],"value_text":"Three-year term, one-time start-up fee of $15,500, monthly account management fee of $7,000"},"claim":"Onconetix, Inc. entered into Exclusive Distribution Agreement with Cardinal Health 105, LLC valued at Three-year term, one-time start-up fee of $15,500, monthly account management fee of $7,000 (effective 2023-09-20).","evidence_excerpt":"On September 21, 2023, Blue Water Biotech, Inc. (the \"Company\") entered into an Exclusive Distribution Agreement (the \"Exclusive Distribution Agreement\"), effective as of September 20, 2023 (the \"Effective Date\"), with Cardinal Health 105, LLC (\"Cardinal Health\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001013762-23-000742","anchor_url":"https://secwatch.observer/filing/0001013762-23-000742#claim-07040c791f7ce2229e271daf7e39db1106609a34","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/0001013762-23-000742-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"9da10cae99e01aee6c6ad19886efadc4ae1469a6","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-09-22T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-03-16","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2023-09-18","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"September 18, 2023, Blue\nWater Biotech, Inc., a Delaware corporation (the “ Company ”), received a written notice (the “ Notice ”)\nfrom the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”)\nindicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) which sets\nforth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “ Minimum Bid Requirement ”)\nas the bid price of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), had closed\nbelow $1.00 per share for 30 cons","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-078811","anchor_url":"https://secwatch.observer/filing/0001213900-23-078811#claim-9da10cae99e01aee6c6ad19886efadc4ae1469a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023078811/0001213900-23-078811-index.htm"},{"fact_type":"executive_change","fact_key":"cae7d79b1d","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-09-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-09-02","interim":false,"role":"Member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vuk Jeremić resigned as Member of the Board of Directors at Onconetix, Inc..","evidence_excerpt":"Effective as of September 2, 2023, Vuk Jeremić resigned as a member of the Board of Directors (the “Board”) of Blue Water Biotech, Inc. (the “Company”) as well as from his positions as a member of the Compensation Committee and Nominating and Corporate Governance Committee of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-075413","anchor_url":"https://secwatch.observer/filing/0001213900-23-075413#claim-cae7d79b1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023075413/0001213900-23-075413-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"1aae7c0e1cad4d4551fcfdae94cc6da9ed336f3c","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-08-28T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":"2024-02-10","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-08-22","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"August 22, 2023, Blue Water Biotech, Inc. (the\n“ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”)\nthat the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing Rules ”) as set\nforth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its quarterly report on Form 10-Q for the quarter ended\nJune 30, 2023 (the “ 10-Q ”). Consistent with the Listing Rules, the Company\nhas 60 calendar days from the date of the Notice to provide Nasdaq with a specific plan to achieve and sustain compliance with","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-071247","anchor_url":"https://secwatch.observer/filing/0001213900-23-071247#claim-1aae7c0e1cad4d4551fcfdae94cc6da9ed336f3c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023071247/0001213900-23-071247-index.htm"},{"fact_type":"executive_change","fact_key":"9702cca828","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-08-16","interim":true,"role":"Chief Financial Officer and interim principal executive officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jon Garfield was appointed as Chief Financial Officer and interim principal executive officer at Onconetix, Inc..","evidence_excerpt":"Effective August 16, 2023, Board has appointed Jon Garfield, the Company’s Chief Financial Officer, to serve as the Company’s interim principal executive officer during the pendency of Mr. Sapirstein’s appointment.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-069983","anchor_url":"https://secwatch.observer/filing/0001213900-23-069983#claim-9702cca828","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/0001213900-23-069983-index.htm"},{"fact_type":"executive_change","fact_key":"24cf9665d5","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-09-30","interim":true,"role":"Interim Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"James Sapirstein was appointed as Interim Executive Chairman at Onconetix, Inc..","evidence_excerpt":"the Board appointed James Sapirstein to serve as Interim Executive Chairman, which appointment shall be effective September 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-069983","anchor_url":"https://secwatch.observer/filing/0001213900-23-069983#claim-24cf9665d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/0001213900-23-069983-index.htm"},{"fact_type":"executive_change","fact_key":"22b97c3534","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2023-08-16","interim":false,"role":"Chairman, Chief Executive Officer, and Member of the Board of Directors","role_category":"ceo","successor_name":"James Sapirstein","successor_named":true},"claim":"Joseph Hernandez resigned as Chairman, Chief Executive Officer, and Member of the Board of Directors at Onconetix, Inc..","evidence_excerpt":"Joseph Hernandez resigned as Chairman, Chief Executive Officer, and a member of the Board of Directors (the “Board”) of Blue Water Biotech, Inc. (the “Company”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-069983","anchor_url":"https://secwatch.observer/filing/0001213900-23-069983#claim-22b97c3534","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/0001213900-23-069983-index.htm"},{"fact_type":"material_agreement","fact_key":"2aed2eb74cab10079b9a5eb510e6e0ca1c684813","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-08-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Inducement Letter","agreement_type":"equity_purchase","counterparty":"a certain holder of existing preferred investment options","effective_date":"2023-07-31","item_codes_triggered":["1.01"],"value_text":"approximately $2,709,973"},"claim":"Onconetix, Inc. entered into Inducement Letter with a certain holder of existing preferred investment options valued at approximately $2,709,973 (effective 2023-07-31).","evidence_excerpt":"On July 31, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), entered into a common stock preferred investment options exercise inducement offer letter (the “Inducement Letter”) with a certain holder (the “Holder”) of existing preferred investment options (“PIOs”) to purchase shares of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-061642","anchor_url":"https://secwatch.observer/filing/0001213900-23-061642#claim-2aed2eb74cab10079b9a5eb510e6e0ca1c684813","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023061642/0001213900-23-061642-index.htm"},{"fact_type":"auditor_change","fact_key":"2c380a3026cc83d283f2b4fbc7d1b28560e26bf5","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-07-06T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"EisnerAmper LLP","disagreement_text":null,"effective_date":"2023-07-06","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Onconetix, Inc. engaged EisnerAmper LLP as its auditor.","evidence_excerpt":"On July 6, 2023, the Audit Committee appointed EisnerAmper LLP (“EA”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 and related interim periods.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-055199","anchor_url":"https://secwatch.observer/filing/0001213900-23-055199#claim-2c380a3026cc83d283f2b4fbc7d1b28560e26bf5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023055199/0001213900-23-055199-index.htm"},{"fact_type":"auditor_change","fact_key":"8ce1a37db39d807fecccb6f4d4a173e7032ddde3","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-07-06T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"Mayer Hoffman McCann P.C.","disagreement_text":null,"effective_date":"2023-06-29","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Mayer Hoffman McCann P.C. resigned as auditor of Onconetix, Inc..","evidence_excerpt":"On June 29, 2023, Mayer Hoffman McCann P.C. (“MHM”), Blue Water Biotech, Inc.’s (the “Company”) independent registered public accounting firm, informed the Company that it resigned, effective June 29, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-055199","anchor_url":"https://secwatch.observer/filing/0001213900-23-055199#claim-8ce1a37db39d807fecccb6f4d4a173e7032ddde3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023055199/0001213900-23-055199-index.htm"},{"fact_type":"material_agreement","fact_key":"2eaf033176e9ab089b89a1b10064351fd1beb064","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"asset_purchase","counterparty":"WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC","effective_date":"2023-06-13","item_codes_triggered":["1.01"],"value_text":null},"claim":"Onconetix, Inc. entered into Purchase Agreement with WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC (effective 2023-06-13).","evidence_excerpt":"On June 13, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with WraSer, LLC, a Mississippi limited liability company, Xspire Pharma, LLC, a Mississippi limited liability company (collectively, the “Seller”), and Legacy-Xspire Holdings, LLC, a Delaware limited liability company and the parent company of the Seller (“Parent”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-048740","anchor_url":"https://secwatch.observer/filing/0001213900-23-048740#claim-2eaf033176e9ab089b89a1b10064351fd1beb064","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/0001213900-23-048740-index.htm"},{"fact_type":"governance_change","fact_key":"4910dcc6fe5553db6ba80391db40f68429e048b5","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-06-06T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-05-31","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to reduce stockholder meeting quorum requirement from a majority to one-third of voting power."},"claim":"Onconetix, Inc.: Amended bylaws to reduce stockholder meeting quorum requirement from a majority to one-third of voting power (effective 2023-05-31).","evidence_excerpt":"On May 31, 2023, the Board amended the Company’s bylaws to reduce the quorum requirement at meetings of the Company’s stockholders from a majority of the voting power of the outstanding shares of stock of the Company entitled to vote, to one-third of the voting power of the outstanding shares of stock of the Company entitled to vote, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-046841","anchor_url":"https://secwatch.observer/filing/0001213900-23-046841#claim-4910dcc6fe5553db6ba80391db40f68429e048b5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5232a86152210ded44c861cf37778bd1fd5a89c1","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-06-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-31","outcome":"passed","proposal_text":"Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"-","subject":null,"votes_abstain":"5,889","votes_against":"248,537","votes_for":"9,717,035","votes_withheld":null}]},"claim":"Onconetix, Inc. shareholders approved Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-31 meeting.","evidence_excerpt":"Proposal No. 3 – Ratification of the appointment of independent registered public accounting firm Appointment by the Company’s audit committee of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 9,717,035 248,537 5,889 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-046841","anchor_url":"https://secwatch.observer/filing/0001213900-23-046841#claim-5232a86152210ded44c861cf37778bd1fd5a89c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f071aeb60c2cba7ca8a4cea15bc4d3da37dce21c","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-06-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-31","outcome":"passed","proposal_text":"Amendment to the Amended and Restated 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 550,000 shares from 2,600,000 to 3,150,000 shares","proposal_type":"equity_plan","results":[{"broker_non_votes":"3,107,004","subject":null,"votes_abstain":"14,138","votes_against":"659,202","votes_for":"6,191,117","votes_withheld":null}]},"claim":"Onconetix, Inc. shareholders approved Amendment to the Amended and Restated 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 550,000 shares from 2,600,000 to 3,150,000 shares at the 2023-05-31 meeting.","evidence_excerpt":"Proposal No. 2 – Amendment to 2022 Equity Incentive Plan The amendment to the 2022 Plan to (i) increase the aggregate number of shares of Common Stock which may be issued under the plan by 550,000 shares from 2,600,000 to 3,150,000 shares was approved. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 6,191,117 659,202 14,138 3,107,004","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-046841","anchor_url":"https://secwatch.observer/filing/0001213900-23-046841#claim-f071aeb60c2cba7ca8a4cea15bc4d3da37dce21c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ccfcfd48a876e71eb24e841935f1ac9a490c909e","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-06-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-31","outcome":"passed","proposal_text":"Election of Mr. James Sapirstein as a Class II director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified","proposal_type":"director_election","results":[{"broker_non_votes":"3,107,004","subject":"James Sapirstein","votes_abstain":null,"votes_against":null,"votes_for":"6,207,510","votes_withheld":"656,947"}]},"claim":"Onconetix, Inc. shareholders approved Election of Mr. James Sapirstein as a Class II director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified at the 2023-05-31 meeting.","evidence_excerpt":"Proposal No. 1 – Election of Directors Mr. James Sapirstein was elected as a Class II director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified. The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Vote James Sapirstein 6,207,510 656,947 3,107,004","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-046841","anchor_url":"https://secwatch.observer/filing/0001213900-23-046841#claim-ccfcfd48a876e71eb24e841935f1ac9a490c909e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm"},{"fact_type":"governance_change","fact_key":"e0b4880e8f2024f442b56f653b95158659fbb73a","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-04-24T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-04-21","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to reflect corporate name change to Blue Water Biotech, Inc."},"claim":"Onconetix, Inc.: Amended bylaws to reflect corporate name change to Blue Water Biotech, Inc (effective 2023-04-21).","evidence_excerpt":"In connection with the name change, the Company amended the Company’s bylaws to reflect the corporate name Blue Water Biotech, Inc., also effective on April 21, 2023. No other changes were made to the bylaws.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-031827","anchor_url":"https://secwatch.observer/filing/0001213900-23-031827#claim-e0b4880e8f2024f442b56f653b95158659fbb73a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031827/0001213900-23-031827-index.htm"},{"fact_type":"governance_change","fact_key":"01818b3234e0ea8e494676f0557e45320e9f8f2a","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-04-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-04-21","item_codes_triggered":["5.03"],"summary_text":"Amended Second Amended and Restated Certificate of Incorporation to change corporate name from 'Blue Water Vaccines Inc.' to 'Blue Water Biotech, Inc.'"},"claim":"Onconetix, Inc.: Amended Second Amended and Restated Certificate of Incorporation to change corporate name from 'Blue Water Vaccines Inc.' to 'Blue Water Biotech, Inc.' (effective 2023-04-21).","evidence_excerpt":"On April 21, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), filed an amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from “Blue Water Vaccines Inc.” to “Blue Water Biotech, Inc.” (the “Name Change Amendment”). The name change was effective as of April 21, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-031827","anchor_url":"https://secwatch.observer/filing/0001213900-23-031827#claim-01818b3234e0ea8e494676f0557e45320e9f8f2a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031827/0001213900-23-031827-index.htm"},{"fact_type":"ma_transaction","fact_key":"5ced50eb72a70c7cd9b2ba754194d4749fed5cb8","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-04-20T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-04-19","consideration_text":"$100,000,000","counterparty":"Veru Inc.","effective_date":"2023-04-19","item_codes_triggered":["2.01"]},"claim":"Onconetix, Inc. completed an acquisition involving Veru Inc. for $100,000,000 (closed 2023-04-19).","evidence_excerpt":"of\nthe Transaction The Company\npurchased substantially all of the Seller’s assets, rights and property related to the ENTADFI TM Business\nfor a total possible consideration of $100,000,000 (as described below). The ENTADFI TM Business\ncapitalizes on the demonstrable success of the FDA-approved drug ENTADFI TM for\ntreating benign prostatic hyperplasia and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-031189","anchor_url":"https://secwatch.observer/filing/0001213900-23-031189#claim-5ced50eb72a70c7cd9b2ba754194d4749fed5cb8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm"},{"fact_type":"material_agreement","fact_key":"5ce55eb0486928a3422556f023e682d13b437682","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-04-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Veru Inc.","effective_date":"2023-04-19","item_codes_triggered":["1.01"],"value_text":"total possible consideration of $100,000,000"},"claim":"Onconetix, Inc. entered into Purchase Agreement with Veru Inc. valued at total possible consideration of $100,000,000 (effective 2023-04-19).","evidence_excerpt":"On April 19, 2023, Blue Water Vaccines Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the \"Purchase Agreement\") with Veru Inc., a Wisconsin corporation (the \"Seller\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-031189","anchor_url":"https://secwatch.observer/filing/0001213900-23-031189#claim-5ce55eb0486928a3422556f023e682d13b437682","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm"},{"fact_type":"material_agreement","fact_key":"9ffb60d46e449b9fe41bc1b93792351c1b065c2f","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-03-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"At The Market Offering Agreement","agreement_type":"atm_program","counterparty":"H.C. Wainwright & Co., LLC","effective_date":"2023-03-29","item_codes_triggered":["1.01"],"value_text":"$3,900,000"},"claim":"Onconetix, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at $3,900,000 (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, Blue Water Vaccines Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Agent”), to create an at-the-market equity program under which it may sell up to $3,900,000 of shares of the Company’s common stock (the “Shares”) from time to time through the Agent (the “ATM Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-024177","anchor_url":"https://secwatch.observer/filing/0001213900-23-024177#claim-9ffb60d46e449b9fe41bc1b93792351c1b065c2f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023024177/0001213900-23-024177-index.htm"},{"fact_type":"executive_change","fact_key":"e2a0364efc","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-01-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Tim Ramdeen was appointed as Director at Onconetix, Inc..","evidence_excerpt":"Effective as of January 13, 2023, the Board appointed Tim Ramdeen to replace Ms. Murphy and serve as a member of the Board, chair of the Nominating and Corporate Governance Committee of the Board and a member each of the Compensation Committee and Audit Committee of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-002936","anchor_url":"https://secwatch.observer/filing/0001213900-23-002936#claim-e2a0364efc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023002936/0001213900-23-002936-index.htm"},{"fact_type":"executive_change","fact_key":"48c5fdb8d0","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2023-01-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-01-13","interim":false,"role":"Director","role_category":"director","successor_name":"Tim Ramdeen","successor_named":true},"claim":"Kimberly Murphy resigned as Director at Onconetix, Inc..","evidence_excerpt":"Effective as of January 13, 2023, Kimberly Murphy resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc. (the “Company”), as well as from her positions as chair of the of the Nominating and Corporate Governance Committee of the Board and as member each of the Compensation Committee and Audit Committee of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-002936","anchor_url":"https://secwatch.observer/filing/0001213900-23-002936#claim-48c5fdb8d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023002936/0001213900-23-002936-index.htm"},{"fact_type":"executive_change","fact_key":"7281765eb4","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-11-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vuk Jeremić was appointed as Director at Onconetix, Inc..","evidence_excerpt":"Effective as of November 4, 2022, the Board appointed Vuk Jeremić to serve as a member of the Board and a member of the Nominating and Corporate Governance Committee of the Board and Compensation Committee of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-069929","anchor_url":"https://secwatch.observer/filing/0001213900-22-069929#claim-7281765eb4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390022069929/0001213900-22-069929-index.htm"},{"fact_type":"executive_change","fact_key":"aa4a376ae7","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-11-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Venerable resigned as Director at Onconetix, Inc..","evidence_excerpt":"Effective as of November 4, 2022, Michael Venerable resigned as a member of the Board of Directors (the \"Board\") of Blue Water Vaccines Inc. (the \"Company\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-069929","anchor_url":"https://secwatch.observer/filing/0001213900-22-069929#claim-aa4a376ae7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390022069929/0001213900-22-069929-index.htm"},{"fact_type":"executive_change","fact_key":"15792d3b6c","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2022-03-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-02-23","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"James Sapirstein was appointed as member of the Board at Onconetix, Inc..","evidence_excerpt":"Effective as of February 23, 2022, the Board appointed James Sapirstein to serve as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-010779","anchor_url":"https://secwatch.observer/filing/0001213900-22-010779#claim-15792d3b6c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390022010779/0001213900-22-010779-index.htm"},{"fact_type":"executive_change","fact_key":"ec7dd0f809","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2022-03-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-02-23","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":"James Sapirstein","successor_named":true},"claim":"John Rice resigned as member of the Board of Directors at Onconetix, Inc..","evidence_excerpt":"Effective as of February 23, 2022, John Rice resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-010779","anchor_url":"https://secwatch.observer/filing/0001213900-22-010779#claim-ec7dd0f809","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390022010779/0001213900-22-010779-index.htm"},{"fact_type":"executive_change","fact_key":"4c5ec6dbef","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2022-02-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-02-23","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"James Sapirstein was appointed as member of the Board at Onconetix, Inc..","evidence_excerpt":"Effective as of February 23, 2022, the Board appointed James Sapirstein to serve as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-009250","anchor_url":"https://secwatch.observer/filing/0001213900-22-009250#claim-4c5ec6dbef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390022009250/0001213900-22-009250-index.htm"},{"fact_type":"executive_change","fact_key":"620e09cbe3","cik":1782107,"ticker":"ONCO","company_name":"Onconetix, Inc.","filed_at":"2022-02-24T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-02-23","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":"James Sapirstein","successor_named":true},"claim":"John Rice resigned as member of the Board of Directors at Onconetix, Inc..","evidence_excerpt":"Effective as of February 23, 2022, John Rice resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-009250","anchor_url":"https://secwatch.observer/filing/0001213900-22-009250#claim-620e09cbe3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390022009250/0001213900-22-009250-index.htm"}]}